New Ideas.
Better Results.

Blue Matter is a consulting firm serving the life sciences industry. We strive to bring a new approach to consulting with original ideas that deliver a meaningful impact.

Contact Us

Our Purpose

We are proud to be part of an industry that is pushing the boundaries of science and technology to improve people’s lives. Our role is to help our clients identify unique insights, generate new ideas and drive meaningful results to get the most out of their products, portfolios and teams.

We began our careers in established consulting firms where we developed valuable experience and industry knowledge. During this time, we came to see that rigid processes often interfered with original thinking and led to bloated deliverables packed with mediocre answers.

A group of us like-minded, passionate consultants believed there was a better approach and founded Blue Matter to provide a platform to foster innovation and creativity in consulting.

Our Difference

Industry and scientific knowledge, analysis and insights. Left brain thinking. This is the foundation of our discipline. Creativity and imagination. Constantly challenging conventional thinking and seeking fresh ideas. Right brain thinking. We’re passionate about this; it’s the reason our clients come back.

The key to winning is effective differentiation. And effective differentiation comes from originality–thinking that is grounded in reason and infused with imagination.

"The terrific work you did resulted in a substantial change to our commercial strategy."

- Chairman of the Board, Small Biotech

"Thank you very much for the great work and partnership. You are one of the rare breed of consultants whom I trust. You will always be on my speed dial if we need help with anything."

- Chief Commercial Officer, Small Biotech

"I appreciate all of the great work you have done for our team this past year and look forward to continued partnership in the New Year."

- Chief Commercial Officer, Mid-sized Diagnostic Company

"Your preparation and support has been instrumental in achieving our desired outcome."

- Franchise Commercial Lead, Global Biotech

"Thank you all so much for the extremely successful project...I couldn't be happier with the way that it went."

- Sr. Product Manager, Diagnostic Company

"This project was excellent, from the content development to facilitation. Many, many thanks for the great work!"

- Director of Marketing, Diagnostic Company

"The process was great, I loved that I didn't have to manage you that much. Everything was highly organized and done on time. Quality and originality of thinking was also good."

- Global Commercial Lead, Large Biotech

"Great project. I was learning as we went along; good expertise — brought in examples from other projects."

- Global Commercial Lead, Large Biotech

Our Clients

Our clients include: top global bio-pharmaceutical companies with large, diverse product portfolios to small emerging players with one asset in development, leading diagnostic companies, and investment houses. We work with CEOs, Chief Commercial Officers, Franchise Heads, Product Directors, Functional Area Leaders. 90%+ of our business is from repeat, satisfied customers.

Our Services

Shape Innovative Products

Drive Successful Launches

Build Great Portfolios and Companies

Pathfinder Capabilities

Blue Matter offers in-depth market expertise across North American and European markets.

Our Pathfinder offerings are specifically designed to help growing biopharma companies succeed in European markets.

Learn more: 7 Keys to Success in Europe

Want to Join Our Team?

Blue Matter offers enriching project experiences with a diverse range of strategic, client-facing projects in the exciting and innovative life sciences industry.

Join Our Team


Over a year ago, we made some predictions about what would happen in the #oncology market in 2021. In this article,…

WHITE PAPER: #MedicalAffairs is experiencing big changes as a functional area within #biopharma companies. Our team…

The Oncology Market: A look back at what happened in 2021

Early last year, our team produced a paper entitled Oncology Outlook 2021: Scientific breakthroughs and competitive breakouts.  It was a fun paper to write because it gave us an opportunity to broadly review the market landscape, identify key trends, and make some predictions for 2021.  Predictions are almost always fun, but they’re only valuable if … Read More

Medical Affairs Metamorphosis, Part I: Trends Driving Major Change and What They Mean for Medical Affairs

It’s no secret that change is a constant companion for those who work in the biopharmaceutical industry.  That’s to be expected in any industry that thrives on innovation in the products it develops and the techniques it uses to develop them. Over the past few years, one function has been transforming at a dramatically accelerated … Read More

The CNS Market: 2021 Review & Predictions for 2022

Just over a year ago, we wrote a two-part series on the “quiet revolution” that’s going on in CNS therapies (access part I here and part II here).  The exciting developments in oncology may be grabbing the headlines, but very interesting things are happening in CNS and much of it has flown just under the … Read More

What does COMPASS Pathways’ recent data on psilocybin mean for psychedelic therapies?

In early November of 2021, COMPASS Pathways released phase IIb data on its psilocybin-based therapy for treatment-resistant depression. Varun Renjen, M.D., leader of our CNS team, talks about this data and its implications for COMPASS (and for psychedelics in CNS therapy overall). Read More

Towards Cancer Cures and Chronic Management: Key Trends and Their Commercial Implications

Introduction Over the last decade, advances in cancer care have measurably improved overall survival, and specifically in disease areas with previously high unmet needs such as non-small cell lung cancer (NSCLC) and melanoma1. Importantly, this increased survival is driven by a shift of more patients into two key categories of treatment outcomes: Cure: Defined here … Read More

12 Pitfalls in Europe: Pitfall #5 – Thinking your list price won’t cross borders

At some point, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity.  Europe is attractive and offers vast market potential. But successfully entering Europe is a complex undertaking.  The stakes are high and there are many pitfalls to avoid.  In this series of articles, we’re outlining the 12 … Read More

12 Pitfalls in Europe: Pitfall #4 – Believing EMA marketing authorization = patient access

At some point in its development, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity.  Europe is attractive for various reasons, including its large population, high per-capita spend on healthcare, and vast market potential. But successfully entering Europe is a complex undertaking, and biopharma companies need to know … Read More